Full Text
Downfalls of the FDA Accelerated Approval Pathway – Stringent Controls Must be Invoked to Ensure Prompt Submission of Follow-Up Confirmatory Trial Data

Abstract

Authors

R. Macaulay

Back to Volume 17, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×